Elite Pharmaceuticals files ANDA for generic antimetabolite; $42M market

ELITE PHARMACEUTICALS INC /NV/

Filed Abbreviated New Drug Application with FDA for an undisclosed generic antimetabolite drug.
IQVIA reports annual sales of $42M for the generic market of this product (12 months ending Dec 2022).
Elite is a specialty pharma developing niche generics; facility in Northvale, NJ.

item 7.01 item 9.01

ELITE PHARMACEUTICALS INC /NV/ filing history →

Source: SEC EDGAR

accession 0001493152-23-013037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.